Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

2020 Compensation Changes for Named Executive Officers

On January 10, 2020, the Compensation Committee of the Board of Directors of Idera Pharmaceuticals, Inc. (the "Company") approved compensation for its current named executive officers as set forth in the bullets and the table below:

· The payment of cash bonus awards for 2019;


 · The grant of options to purchase shares of common stock of the Company;

· The grant of restricted stock units; and

· Annual base salaries for 2020.






                                                               Stock          Restricted Stock      2020 Annual
                Name                     2019 Bonus         Options (1)          Units (2)             Salary
          Vincent J. Milano
President and Chief Executive Officer   $    315,000              92,000   

             37,000     $    600,000 (3)(4)
            John J. Kirby
   Senior Vice President and Chief
          Financial Officer             $    114,660 (5)          50,000                 20,000     $    336,000
         R. Clayton Fletcher
   Senior Vice President, Business
       Development & Strategy           $    168,000              50,000                 20,000     $    400,000 (4)
          Jonathan Yingling
    Senior Vice President, Chief
         Scientific Officer             $    168,000              50,000                 20,000     $    400,000 (4)
            Bryant D. Lim
   Senior Vice President, General
        Counsel and Secretary           $    155,232              50,000                 20,000     $    336,000 (4)

(1) Each grant of options to purchase shares of the Company's common stock was

made effective as of January 10, 2020 and pursuant to the Company's 2013

Stock Incentive Plan. The exercise price is $1.79 per share, which is equal

to the closing price of the Company's common stock on the Nasdaq Capital

Market on the date of grant. Subject to the recipient's continued employment

with the Company on the applicable vesting date, the option award shall vest

with respect to 25% of the underlying shares on the first anniversary of the

date of grant and with respect to the balance of the underlying shares shall

vest in twelve equal quarterly installments following the first anniversary


     of the date of grant.

(2) Each of the restricted stock units, representing a right to receive one share

of the Company's common stock, was granted effective as of January 10, 2020

and pursuant to the Company's 2013 Stock Incentive Plan. Subject to the

recipient's continued employment with the Company on the applicable vesting

date, 25% of the shares subject to each restricted stock unit award shall


     vest on each one-year anniversary of the date of grant.

(3) See below for discussion regarding the payment of Mr. Milano's 2020 annual


     salary.

(4) No change from base salary effective January 1, 2019.

(5) Mr. Kirby was appointed Senior Vice President and Chief Financial Officer on

July 23, 2019; the 2019 Bonus was pro-rated.

Amendment to Employment Agreement





On January 10, 2020 (the "Effective Date"), the Company entered into an
Amendment to Employment Agreement (the "Amendment") with its Chief Executive
Officer, Mr. Vincent J. Milano, amending that certain Employment Agreement, by
and between the Company and Mr. Milano, dated December 1, 2014 (as described in
the Current Report on Form 8-K filed with the Securities Exchange Commission
(the "SEC") on November 24, 2014).



Pursuant to the Amendment, Mr. Milano's annual base salary of $600,000 shall be
payable as follows: (i) for the period from January 1, 2020 to the Effective
Date, $18,181.84 was payable in cash; and (ii) for the period immediately
following the Effective Date to December 31, 2020, an additional $6,600 shall be
payable in cash and $575,218.16 shall be payable in the form of a restricted
stock unit grant to be granted to Mr. Milano on December 18, 2020 (the "RSU
Award"). The RSU Award will be granted pursuant to the Company's 2013 Stock
Incentive Plan and in accordance with the terms and conditions set forth in a
Restricted Stock Unit Agreement (the "Award Agreement") to be entered into by
the Company and Mr. Milano at the time of the grant.



The descriptions of the Amendment and the form of Award Agreement are qualified
in their entirety by references to the Amendment and the Award Agreement, copies
of which are filed herewith as Exhibit 10.1 and Exhibit 10.2.

Item 7.01 Regulation FD Disclosure.





On January 15, 2020, the Company uploaded a presentation to its website,
www.iderapharma.com, discussing the state of the Company. We may rely on all or
part of this presentation any time we are discussing the current state of the
Company in communications with investors or at conferences. A copy of the
presentation is attached to this Current Report on Form 8-K as Exhibit 99.1

(the
"Presentation").



The information contained in the Presentation is summary information that is
intended to be considered in the context of the Company's SEC filings and other
public announcements that the Company may make, by press release or otherwise,
from time to time. The Company undertakes no duty or obligation to publicly
update or revise the information contained in this report, although it may do so
from time to time as its management believes is warranted. Any such updating may
be made through the filing of other reports or documents with the SEC, through
press releases or through other public disclosure.



The Company is furnishing the information in this Item 7.01 and the related
Exhibit 99.1 filed herewith to comply with Regulation FD. Such information shall
not be deemed to be "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, and shall not be deemed to be incorporated by
reference into any of the Company's filings under the Securities Act of 1933, as
amended, whether made before or after the date hereof and regardless of any
general incorporation language in such filings, except to the extent expressly
set forth by specific reference in such a filing. This Item 7.01 will not be
deemed an admission as to the materiality of any information herein (including
Exhibit 99.1) that is required to be disclosed solely by Regulation FD.


Item 9.01.     Financial Statements and Exhibits.



(d) Exhibits.




Exhibit Number                               Description
  10.1             Amendment to Employment Agreement, dated January 10, 2020, by and
                 between the Company and Vincent J. Milano
  10.2             Form of Vincent J. Milano Restricted Stock Unit Agreement
  99.1             Investor Presentation dated January 15, 2020

© Edgar Online, source Glimpses